Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytoto...

por Bellone, S, Roque, D, Cocco, E, Gasparrini, S, Bortolomai, I, Buza, N, Abu-Khalaf, M, Silasi, D-A, Ratner, E, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2012

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

por Schwab, C L, Bellone, S, English, D P, Roque, D M, Lopez, S, Cocco, E, Nicoletti, R, Bortolomai, I, Bonazzoli, E, Ratner, E, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Santin, A D
Publicado 2014

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy

por Bellone, S, Tassi, R, Betti, M, English, D, Cocco, E, Gasparrini, S, Bortolomai, I, Black, J D, Todeschini, P, Romani, C, Ravaggi, A, Bignotti, E, Bandiera, E, Zanotti, L, Pecorelli, S, Ardighieri, L, Falchetti, M, Donzelli, C, Siegel, E R, Azodi, M, Silasi, D-A, Ratner, E, Schwartz, P E, Rutherford, T J, Santin, A D
Publicado 2013